NovaVive Inc. - Canine

01/16/2025

NovaVive’s production process adheres to strict sterility standards, and all products undergo in-house testing to ensure purity, safety and potency.

Each batch is then reviewed by the USDA prior to its release into the market.

Visit NovaVive.ca for more information.

01/10/2025

Finnegan sadly lost his battle with cancer just after Christmas. However, we were glad to be able to offer some comfort in the last few months of his life post-amputation.

Our Immunocidin immunotherapy is regulator-approved in the USA and Canada for the treatment of canine mammary cancer, but it is being used experimentally to treat a variety of other cancer types.

Immunocidin has also proven helpful as a palliative (end-of-life) support for dogs when treatment is no longer an option.

Learn more at NovaVive.ca/products or ask your veterinarian to contact us.

01/08/2025

We were sad to learn about the passing of Zoey, but we were pleased to help her live her best life for more than 4 years despite her cancer diagnosis.

Our Immunocidin immunotherapy is regulator-approved in the USA and Canada for the treatment of canine mammary cancer, but it is being used experimentally to treat a variety of other cancer types.

Immunocidin has also proven helpful as a palliative (end-of-life) support for dogs when treatment is no longer an option.

Learn more at NovaVive.ca/products or ask your veterinarian to contact us.

01/02/2025

Seneca Park Zoo in Rochester, NY has been using Immunocidin immunotherapy as an experimental treatment for a bladder mass in Katya the tiger.

Katya has been comfortable and eating well and has been urinating normally over the course of treatment. Zoo staff are training Katya to allow voluntary ultrasound to evaluate her bladder and see if the mass is shrinking.

Immunocidin® is regulator-approved in the USA and Canada as an intratumoral treatment for canine mammary cancer. It is undergoing research in various other tumor types.

12/24/2024

NovaVive extends the very best of the season to you and your loved ones … and wishes you a happy, healthy, and successful new year.

See you in 2025!

12/24/2024

Immunocidin is approved by regulators in the USA and Canada for the treatment of canine mammary cancer and is undergoing further research in other tumor types like osteosarcoma.

We’re pleased to help dogs like Tank live their best lives despite a cancer diagnosis.

Visit NovaVive.ca/products to learn more.

12/17/2024

Please enjoy reading the latest quarterly business update newsletter from NovaVive - Volume 10, Issue 4 - https://tinyurl.com/r7h88mxe

11/28/2024

Immunocidin® immunotherapy works by stimulating direct and indirect anticancer activity in the dog.

The product is approved in the USA and Canada for treating canine mammary cancer and research is ongoing in other tumor types.

Visit NovaVive.ca/products to learn more.

11/21/2024

As an immunotherapy, Immunocidin stimulates both direct and indirect anticancer activity by boosting a dog’s immune system to fight the disease.

Immunotherapy can behave similar to chemotherapy but tends not to have as severe a side effect profile.

Immunocidin is regulator-approved in the USA and Canada for the intratumoral treatment of canine mammary cancer, but research is ongoing using the product to treat various tumor types and using alternative modes of administration (including IV and oral).

For further information, visit our canine research web page - http://novavive.ca/canine-research

11/12/2024

Seeing our beloved pets reach the end of their lives is difficult. Often, there are no further treatment options and we must face losing them.

Immunocidin immunotherapy has been used as a palliative treatment to help pets stay comfortable. Ask your veterinarian about Immunocidin or visit NovaVive.ca/products for more information.

11/11/2024

10/29/2024

NovaVive offers an immunotherapeutic alternative for the treatment of canine cancer that is USDA- and CFIA-approved for mammary adenocarcinoma - Immunocidin®.

By stimulating the immune system, Immunocidin has both a direct and indirect effect on tumor cells.

Beyond the anticancer effect, owners report that their treated pets have a good quality of life in terms of appetite, sleep, energy and overall comfort.

Ask your veterinarian about Immunocidin.

10/22/2024

We were sad to hear of the passing of Six, but we are pleased to have helped her live her best life for almost two years with Immunocidin.

This immunotherapy is regulator-approved in the USA and Canada for treating canine mammary cancer and is undergoing further research in other tumor types in both dogs and cats.

Learn more at http://novavive.ca/canine-research

10/15/2024

Immunocidin immunotherapy is approved by regulators in the USA and Canada for the treatment of canine mammary cancer.

NovaVive continues to explore other cancers for which Immunocidin may be effective. One of these is osteosarcoma (bone cancer).

Learn more about Immunocidin research at http://novavive.ca/canine-research.

10/09/2024

Immunocidin® immunotherapy has proven safe and effective as an intratumoral treatment for canine mammary cancer. Further research has demonstrated that it can also be safely administered by IV injection.

Immunocidin is approved by regulators in the USA and Canada. Research is ongoing with this product in various tumor types using different administration methods.

Visit NovaVive.ca/products for more information.

09/24/2024

Immunocidin has a two-way mode of action. It stimulates the immune system to fight cancer and the DNA of the active ingredient kills cancer cells.

This product is approved by regulators in the USA and Canada for the treatment of canine mammary cancer and is undergoing further research in other tumor types.

Visit NovaVive.ca/products to learn more.

09/24/2024

Please enjoy reading our latest quarterly business update newsletter (Volume 10, Issue 3) - https://tinyurl.com/twt9hfvx